Table 1.
Incidence of notified pertussis, vaccines, vaccination schedules and coverage in Spain and Dominican Republic, 2005–2014
| Country | Global Incidence per 100,000 inhab.a | Incidence per 100,000 inhab. ≤1 year-old | Vaccine | Manufacturer | Global coverageb (%) | Vaccination Schedulec (type vaccine) |
|---|---|---|---|---|---|---|
| Spain (Iberian country) | 3.4 (0.5–8,4) | 813.3 |
Infanrix Hexa® Infanrix VPI Hib® Pentavac® |
GlaxoSmithKline Biologicals, S.A. Sanofi Pasteur MSD, S.A. |
96.5 | Primary: 2, 4, 6 mo. Booster: 15–18 mo and 4–6 yr (DTaP) |
| DR (Caribbean country) | 12.1 (1.0–37.0) | 132.0 |
Quinvaxem® Tritanrix® HB DTCHepB.Hib® |
GlaxoSmithKline Biologicals, S.A. | 82.2 | Primary: 2, 4, 6 mo. Booster: 18 mo and 4 yr (DTwP) |
aCare should be taken when comparing incidences between countries because of the different surveillance and diagnostic methods used
bcoverage in children aged 2, 4 and 6 months (primary series coverage in children)
ctwo booster doses are given in DR and Spain at the age of 18 months and 4 years-old, and between 4–6 years